UCB has announced positive results of a Phase 3 non-inferiority study designed to compare efficacy and safety of lacosamide to carbamazepine-CR (controlled release; retard tablets) as monotherapy in newly or recently diagnosed adult patients with ... Medical News Today, 4 days ago
UCB with positive results for Vimpat® (lacosamide) in EU Phase 3 monotherapy study - Edu Bourse, 4 days ago
UCB announces positive results of lacosamide non-inferiority Phase III study - Pharma Letter, 4 days ago
Among all pharmaceuticals, oral dosages are preferred, when pharmacokinetics permit them. And among oral dosages, oral solids—pills—are the most common form. But there have been, and will continue to be, a significant number of drugs that are ...Pharmaceutical Commerce, 1 week ago
on your WebpageAdd Widget >Get your members hooked!